Moussa Lingani

Ganaplacide (KAF156) plus lumefantrine solid dispersion formulation combination for uncomplicated Plasmodium falciparum malaria: an open-label, multicentre, parallel-group, randomised, controlled, phase 2 trial

Bernhards Ogutu, Adoke Yeka, Sylvia Kusemererwa et al. · The Lancet Infectious Diseases · 2023 · 40 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

In vivo/ex vivo efficacy of artemether–lumefantrine and artesunate–amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso

Moussa Lingani, Léa Nadège Bonkian, Isidore Yerbanga et al. · Malaria Journal · 2020 · 37 citations · Full text

Medicine, Infectious Diseases, Pharmacology +16

Ex vivo anti-malarial drugs sensitivity profile of Plasmodium falciparum field isolates from Burkina Faso five years after the national policy change

Halidou Tinto, Léa Nadège Bonkian, Louis Arnaud Nana et al. · Malaria Journal · 2014 · 33 citations · Full text

Medicine, Pharmacology, Antimicrobial Pharmacology +16

The changing epidemiology of hepatitis B and C infections in Nanoro, rural Burkina Faso: a random sampling survey

Moussa Lingani, Tomoyuki Akita, Serge Ouoba et al. · BMC Infectious Diseases · 2020 · 23 citations · Full text

Veterinary Medicine, Infectious Diseases, Maternal Health +16

Randomized, open-label, phase 2a study to evaluate the contribution of artefenomel to the clinical and parasiticidal activity of artefenomel plus ferroquine in African patients with uncomplicated Plasmodium falciparum malaria

Adama Gansané, Moussa Lingani, Adoke Yeka et al. · Malaria Journal · 2023 · 19 citations · Full text

Medicine, Infectious Diseases, Pharmacology +15